All News
My volume of referrals for OCI or degenerative disease (or sometimes completely normal SI joints) read as "sacroiliiitis" really does seem to have been increasing lately @lihi_eder @RheumNow #RNL2024 https://t.co/vksNCaADck
Richard Conway RichardPAConway ( View Tweet)
👉“Eighty percent of drugs withdrawn from the market pose greater risk for women.” – Dr. Eder #RNL2024 @rheumnow #genderDifferences https://t.co/RZrIdvecbY
TheDaoIndex KDAO2011 ( View Tweet)
Welcome to the "FDA-approved" team Bimekizumab. Dr. Armstrong shows MOA of IL17a and IL17f dual inhibition, and the important PASI scores showing 2/3 of pts clear by week 16. @RheumNow #RNL2024 @_AprilArmstrong https://t.co/KiTcVsGzpD
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. April Armstrong shares a beautiful picture around pathophysiology in PsO/PsA, as demonstrated in a non-joint graphic below. "Consider the domains when choosing biologics." #RNL2024 @RheumNow @_AprilArmstrong https://t.co/2nUAUYZLL3
Dr. Rachel Tate uptoTate ( View Tweet)
The different outcomes and response to treatment in males and females are related to sex differences in pain mechanisms and gender roles. Women report a higher BASDAI level, the ASDAS is equal in both sexes, Lihi Eder #RNL2024 @RheumNow https://t.co/7jjkgmmUg8
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Radiographic changes are more common and severe in males with PsA. Over-weighting radiographic changes in your clinical reasoning will lead to missed diagnoses in women @lihi_eder @RheumNow #RNL2024 https://t.co/3OpMt7QaU8
Richard Conway RichardPAConway ( View Tweet)
Did you know?! Remission criteria perform differently in men and women with rheumatic diseases; studies really do NOT account for this. – Dr. Eder #RNL2024 @rheumnow https://t.co/2JOTyD1GDZ
TheDaoIndex KDAO2011 ( View Tweet)
Differences in presentation of PsA in men and women. Crucial to incorporate this into your diagnostic formulation @lihi_eder @RheumNow #RNL2024 https://t.co/uvnU1ujCX7
Richard Conway RichardPAConway ( View Tweet)
Picking the right tools to measure disease activity may be difficult because these tools may perform differently in men and women. The ASDAS show to differences between sexes but the BASDAI was significantly higher in women than in men. – Dr. Eder #RNL2024 @rheumnow https://t.co/KSBMrxio5P
TheDaoIndex KDAO2011 ( View Tweet)
Key take home points from @_AprilArmstrong on psoriatic disease @RheumNow #RNL2024 https://t.co/Svx9gNKBuR
Richard Conway RichardPAConway ( View Tweet)
Potential board question: be able to differentiate between osteitis condensan ilii vs sacroiliitis. With osteitis condensan, the SI joint is normal, with no irregularity, erosions, or loss of joint space. Sclerosis is predominantly on the iliac bone @rheumnow #RNL2024 @rheumnow https://t.co/mimcdoufEE
TheDaoIndex KDAO2011 ( View Tweet)
Men with PsA have more severe psoriasis, axial disease, high CRP, erosive disease compared to women, but women tend to have more pain. Delay to diagnosis in female patients are likely related to these differences- Dr. Eder #RNL2024 @rheumnow https://t.co/S9dzANITfH
TheDaoIndex KDAO2011 ( View Tweet)
Nice summary of data as to why IL-17 or IL-23 are generally favoured by dermatology for psoriasis @_AprilArmstrong @RheumNow #RNL2024 https://t.co/qfAn2AHilX
Richard Conway RichardPAConway ( View Tweet)
Dr. Eder on gender differences – we need to move from gender blind to gender specific approach to treating our patients. There are biological, cultural, and social differences between males and females. #RNL2024 @rheumnow https://t.co/gnzU6FKIPR
TheDaoIndex KDAO2011 ( View Tweet)
Key takeaways when choosing therapies anti-TNFs, IL-17i, IL-23i, JAKs and TYK-2, in psoriasis. Think of skin, joint and spine involvement, April Armstrong #RNL2024 @RheumNow https://t.co/nUMmQk4xZq
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Considerations in choosing a biologic in psoriatic disease from dermatology viewpoint @_AprilArmstrong @RheumNow #RNL2024 https://t.co/PHg0CBjTkC
Richard Conway RichardPAConway ( View Tweet)
#RNL2024 @RheumNow
@_AprilArmstrong: Deucravacitinib v Apremilast
Deucra: TYK2 inhibitor, approved for PsO (not yet PsA)
Superior to apremilast for skin disease (sPGA) https://t.co/NRnsm4cOum
Eric Dein ericdeinmd ( View Tweet)
Dr. A. Armstrong's Key Takeaways for PsO.
TNFi - great in PsA and pregnancy
IL-17i - robust PsO efficacy and in PsA
IL-23i - robust in PsO, fewer injections, and efficacious in PsA.
#RNL2024 @RheumNow @_AprilArmstrong https://t.co/j8LaOGITuf
Dr. Rachel Tate uptoTate ( View Tweet)
Did you know of all the small oral molecules, #apremilast is the only one approved for all stages of #psoriasis (mild to severe)? - Dr. Armstrong polls the audience on their thoughts then revealing the correct answer #RNL2024 @rheumnow https://t.co/NXSiaaGp3p
TheDaoIndex KDAO2011 ( View Tweet)
Dr. A. Armstrong shares dermatology/dermatologist trends in PsO.
1. They tend to shorted then interval between injections as opposed to the amount of medication per dose.
2. Derms generally wait 6 months to switch meds
3. Like rheums, derms tend to switch classes (of tx agent)… https://t.co/HWbJMwnwkE https://t.co/bgKw7ynANN
Links:
Dr. Rachel Tate uptoTate ( View Tweet)